Pilot Study of Safety and Efficacy of Combined Use of Dipeptidyl-Peptidase Inhibitor (Sitagliptin), Proton Pump Inhibitor (Pantoprazole) and Metformin to Prevent Beta-Cell Apoptosis and Promote Islet Regeneration in Islet Transplant Recipients With Early Graft Dysfunction.

Trial Profile

Pilot Study of Safety and Efficacy of Combined Use of Dipeptidyl-Peptidase Inhibitor (Sitagliptin), Proton Pump Inhibitor (Pantoprazole) and Metformin to Prevent Beta-Cell Apoptosis and Promote Islet Regeneration in Islet Transplant Recipients With Early Graft Dysfunction.

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Apr 2016

At a glance

  • Drugs Pantoprazole (Primary) ; Sitagliptin (Primary) ; Metformin
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 17 Apr 2016 Results published in the Diabetic Medicine
    • 17 Jun 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 20 Oct 2011 Planned End Date changed from 1 Sep 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top